Market Highlights
Pemphigus is a group of IgG-mediated autoimmune diseases of the skin and oral mucosa which causes blister and erosions on the skin. In pemphigus immune system mistakenly produces antibodies that attack healthy cells in skin and mucosa. Sometimes it may also occur due to a side effect of medication such as blood pressure drugs. Blisters that occurs on the skin may be referred to as flaccid bullae because they are not firm, and break opens easily.
Factors such as increasing prevalence of cancer, awareness regarding oral hygiene and unhealthy lifestyle drive the global pemphigus market growth. Whereas rising investment in research and development activities and increasing healthcare expenditure are few more propellents of global pemphigus market.
On the other hand, the lack of awareness regarding cancer and stringent regulation may hamper the growth of the market.
The global pemphigus market is dominated by many market players. The key players in the market are engaged in new launches and strategic collaborations to hold its market position.
Segmentation
The global pemphigus market has been segmented into types, diagnosis, treatment and end users. Based on types of pemphigus the market is further segmented into pemphigus vulgaris, pemphigus foliaceus, pemphigus vegetans, paraneoplastic pemphigus.
The market on the basis of diagnosis has been segmented into skin peeling, skin biopsy, run blood tests, endoscopy.
The market, by treatment, has been segmented corticosteroids, initial therapy, maintenance therapy
immunosuppressants, biological therapies, intravenous immunoglobulin (IVIG) therapy, other medication.
Based on end-user market is segmented into hospitals, clinics, laboratories.
Key Players
Some of the key players in the global pemphigus market are Novartis Pharmaceuticals, Hoffmann-La Roche, Principia Biopharma, Inc, Argenx, Sanofi S.A., Pfizer Inc., Teligent Inc, GlaxoSmithKline LLC, and Teva Pharmaceutical Industries.
https://www.marketresearchfuture.com/reports/pemphigus-market-6486